Arvinas’ $115 Million Follow-On Public Offering

Goodwin advised Goldman Sachs & Co. LLC as a representative of several underwriters on a follow-on public offering for Arvinas, Inc. of $115 million of shares of its common stock.

Arvinas, Inc. is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is creating a new class of drugs based on targeted protein degradation.

The Goodwin team was led by Rob Puopolo (Picture), Seo Salimi, Will Magioncalda and Nikhil Sethi (Corporate); Duncan Greenhalgh and Olivia Uitto (IP); and Stephanie Philbin and Steve Tjoe (FDA Regulatory).

Involved fees earner: Duncan Greenhalgh – Goodwin Procter; William Magioncalda – Goodwin Procter; Stephanie Philbin – Goodwin Procter; Robert Puopolo – Goodwin Procter; Seo Salimi – Goodwin Procter; Steven Tjoe – Goodwin Procter; Olivia Uitto – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: Goldman Sachs & Co.;

Author: Ambrogio Visconti